Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Non-Current Assets (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Non-Current Assets for 5 consecutive years, with $11.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 19.34% to $11.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $50.2 million, a 50.22% decrease, with the full-year FY2024 number at $13.9 million, down 61.98% from a year prior.
  • Non-Current Assets was $11.5 million for Q3 2025 at Werewolf Therapeutics, down from $12.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $38.5 million in Q1 2023 to a low of $4.0 million in Q3 2021.
  • A 5-year average of $19.8 million and a median of $18.2 million in 2021 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: surged 424.73% in 2022, then tumbled 63.82% in 2025.
  • Werewolf Therapeutics' Non-Current Assets stood at $18.2 million in 2021, then increased by 10.25% to $20.0 million in 2022, then soared by 81.91% to $36.5 million in 2023, then plummeted by 61.98% to $13.9 million in 2024, then fell by 17.38% to $11.5 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Non-Current Assets are $11.5 million (Q3 2025), $12.1 million (Q2 2025), and $12.8 million (Q1 2025).